Site-directed in vitro immunization leads to a complete human monoclonal IgG4 lambda that binds specifically to the CDR2 region of CTLA-4 (CD152) without interfering the engagement of natural ligands.
BACKGROUND
The ability to acquire fully human monoclonal antibodies (mAbs) with pre-defined specificities is critical to the development of molecular tags for the analysis of receptor function in addition to promising immunotherapeutics. Yet most of the arriving affinity maturated and complete human immunoglobulin G (IgG) molecules, which are actually derived from single human B cells, have not widely been used to study the conserved self antigens (Ags) such as CD152 (cytotoxic T lymphocyte antigen-4, CTLA-4) because proper hosts are lacking.


RESULTS
Here we developed an optimized protocol for site-directed in vitro immunizing peripheral blood mononuclear cells (PBMC) by using a selected epitope of human CD152, an essential receptor involved in down-regulation of T cell activation. The resultant stable trioma cell lines constantly produce anti-CD152 mAb (gamma4lambdahuCD152), which contains variable (V) regions of the heavy chain and the light chain derived from the VH3 and V lambda human germline genes, respectively, and yet displays an unusual IgG4 isotype. Interestingly, gamma4lambdahuCD152 has a basic pI not commonly found in myeloid monoclonal IgG4 lambdas as revealed by the isoelectric focusing (IEF) analysis. Furthermore, gamma4lambdahuCD152 binds specifically, with nanomolar affinity, to an extracellular constituency encompassing the putative second complementarity determining region (CDR2) of CD152, whereby it can react to activated CD3+ cells.


CONCLUSIONS
In a context of specific cell depletion and conditioned medium,in vitro induction of human Abs against a conserved self Ag was successfully acquired and a relatively basic mAb, gamma4lambdahuCD152, with high affinity to CDR2 of CD152 was thus obtained. Application of such a human IgG4 lambda mAb with designated CDR2 specificity may impact upon and prefer for CD152 labeling both in situ and ex situ, as it does not affect the binding of endogenous B7 ligands and can localize into the confined immunological synapse which may otherwise prevent the access of whole IgG1 molecules.
Chin
Li-Te
LT
Graduate Institute of Life Science, Fu-Jen Catholic University, Taipei, Taiwan, RoC. ltc0553@ms42.hinet.net
Chu
Chishih
C
Chen
Han-Min
HM
Hsu
Shu-Ching
SC
Weng
Bor-Chun
BC
Chu
Chi-Hong
CH
D000595:Amino Acid Sequence; D000818:Animals; D000911:Antibodies, Monoclonal / Q000235:genetics / Q000276:immunology*; D015703:Antigens, CD / Q000235:genetics / Q000276:immunology*; D000943:Antigens, Differentiation / Q000235:genetics / Q000276:immunology*; D060908:CTLA-4 Antigen; D002460:Cell Line; D002478:Cells, Cultured; D022801:Complementarity Determining Regions / Q000235:genetics / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D000939:Epitopes / Q000235:genetics / Q000276:immunology; D005434:Flow Cytometry; D006801:Humans; D006825:Hybridomas / Q000276:immunology; D015151:Immunoblotting; D007074:Immunoglobulin G / Q000235:genetics / Q000276:immunology*; D007146:Immunoglobulin lambda-Chains / Q000235:genetics / Q000276:immunology; D007158:Immunologic Techniques; D007526:Isoelectric Point; D008024:Ligands; D008969:Molecular Sequence Data; D017422:Sequence Analysis, DNA
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000943:Antigens, Differentiation; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D022801:Complementarity Determining Regions; D000939:Epitopes; D007074:Immunoglobulin G; D007146:Immunoglobulin lambda-Chains; D008024:Ligands
J Biol Chem. 1996 Oct 25;271(43):26762-71
8900156
J Exp Med. 1996 Jun 1;183(6):2533-40
8676074
J Immunol Methods. 1997 Jan 15;200(1-2):181-90
9005957
J Exp Med. 1997 Feb 3;185(3):393-403
9053440
Clin Exp Immunol. 1999 Mar;115(3):451-7
10193417
Science. 1999 Jul 9;285(5425):221-7
10398592
Tissue Antigens. 2000 Mar;55(3):229-38
10777098
J Immunol. 2000 Aug 1;165(3):1352-6
10903737
J Immunol. 2000 Sep 15;165(6):3037-42
10975813
Nature. 2001 Mar 29;410(6828):604-8
11279501
Nature. 2001 Mar 29;410(6828):608-11
11279502
J Exp Med. 2001 Jun 4;193(11):1303-10
11390437
J Immunol. 2001 Nov 15;167(10):5636-44
11698435
Immunology. 2002 Jan;105(1):9-19
11849310
Nat Rev Immunol. 2002 Feb;2(2):116-26
11910893
Nat Immunol. 2002 May;3(5):427-34
11976720
Biotechniques. 2002 Sep;33(3):680, 682, 684 passim
12238778
Curr Opin Biotechnol. 2002 Dec;13(6):593-7
12482519
Curr Opin Biotechnol. 2002 Dec;13(6):598-602
12482520
J Immunol. 2004 May 15;172(10):5948-56
15128776
Diabetes. 1988 Sep;37(9):1202-11
3410164
Immunology. 1989 Apr;66(4):485-90
2541070
J Exp Med. 1991 Sep 1;174(3):561-9
1714933
Immunology. 1994 Mar;81(3):428-34
7515847
Annu Rev Immunol. 1994;12:433-55
8011287
J Exp Med. 1994 Dec 1;180(6):2049-58
7964482
Proc Natl Acad Sci U S A. 1995 Jan 31;92(3):811-5
7846057
Eur J Immunol. 1995 Mar;25(3):657-63
7535699
Immunology. 1996 Sep;89(1):1-7
8911132